Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Lung cancer is the leading cause of cancer-related mortality in the United States, and accurate staging plays a vital role in determining prognosis and treatment. The recently revised eighth edition of the TNM staging system for lung cancer defines new T and M descriptors and updates stage groupings on the basis of substantial differences in survival. There are new T descriptors that are based on the findings at histopathologic examination, and T descriptors are reassigned on the basis of tumor size and extent. No changes were made to the N descriptors in the eighth edition of the TNM staging of lung cancer, because the four N categories that are based on the location of the diseased nodes can be used to consistently predict prognosis. The eighth edition includes a new M1b descriptor for patients with a single extrathoracic metastatic lesion in a single organ (M1b), because they have better survival and different treatment options, compared with those with multiple extrathoracic lesions (M1c). Examination with fluorine 18 fluorodeoxyglucose (FDG) PET/CT is the standard of care and is an integral part of the clinical staging of patients with lung cancer. To provide the treating physicians with accurate staging information, radiologists and nuclear medicine physicians should be aware of the updated classification system and should be cognizant of the site-specific strengths and limitations of FDG PET/CT. In this article, the eighth edition of the TNM staging system is reviewed, as well as the role of FDG PET/CT in the staging of non-small cell lung carcinoma.

Original languageEnglish (US)
Pages (from-to)2134-2149
Number of pages16
JournalRadiographics : a review publication of the Radiological Society of North America, Inc
Volume38
Issue number7
DOIs
StatePublished - Nov 1 2018

Fingerprint

Neoplasm Staging
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Physicians
Survival
Nuclear Medicine
Fluorodeoxyglucose F18
Standard of Care
Neoplasms
Mortality
Therapeutics

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

@article{43297cdfd34448a0bacced44dfd76aab,
title = "Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer",
abstract = "Lung cancer is the leading cause of cancer-related mortality in the United States, and accurate staging plays a vital role in determining prognosis and treatment. The recently revised eighth edition of the TNM staging system for lung cancer defines new T and M descriptors and updates stage groupings on the basis of substantial differences in survival. There are new T descriptors that are based on the findings at histopathologic examination, and T descriptors are reassigned on the basis of tumor size and extent. No changes were made to the N descriptors in the eighth edition of the TNM staging of lung cancer, because the four N categories that are based on the location of the diseased nodes can be used to consistently predict prognosis. The eighth edition includes a new M1b descriptor for patients with a single extrathoracic metastatic lesion in a single organ (M1b), because they have better survival and different treatment options, compared with those with multiple extrathoracic lesions (M1c). Examination with fluorine 18 fluorodeoxyglucose (FDG) PET/CT is the standard of care and is an integral part of the clinical staging of patients with lung cancer. To provide the treating physicians with accurate staging information, radiologists and nuclear medicine physicians should be aware of the updated classification system and should be cognizant of the site-specific strengths and limitations of FDG PET/CT. In this article, the eighth edition of the TNM staging system is reviewed, as well as the role of FDG PET/CT in the staging of non-small cell lung carcinoma.",
author = "Asha Kandathil and Kay, {Fernando Uliana} and Yasmeen Butt and Wachsmann, {Jason W} and Rathan Subramaniam",
year = "2018",
month = "11",
day = "1",
doi = "10.1148/rg.2018180060",
language = "English (US)",
volume = "38",
pages = "2134--2149",
journal = "Radiographics",
issn = "0271-5333",
publisher = "Radiological Society of North America Inc.",
number = "7",

}

TY - JOUR

T1 - Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer

AU - Kandathil, Asha

AU - Kay, Fernando Uliana

AU - Butt, Yasmeen

AU - Wachsmann, Jason W

AU - Subramaniam, Rathan

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Lung cancer is the leading cause of cancer-related mortality in the United States, and accurate staging plays a vital role in determining prognosis and treatment. The recently revised eighth edition of the TNM staging system for lung cancer defines new T and M descriptors and updates stage groupings on the basis of substantial differences in survival. There are new T descriptors that are based on the findings at histopathologic examination, and T descriptors are reassigned on the basis of tumor size and extent. No changes were made to the N descriptors in the eighth edition of the TNM staging of lung cancer, because the four N categories that are based on the location of the diseased nodes can be used to consistently predict prognosis. The eighth edition includes a new M1b descriptor for patients with a single extrathoracic metastatic lesion in a single organ (M1b), because they have better survival and different treatment options, compared with those with multiple extrathoracic lesions (M1c). Examination with fluorine 18 fluorodeoxyglucose (FDG) PET/CT is the standard of care and is an integral part of the clinical staging of patients with lung cancer. To provide the treating physicians with accurate staging information, radiologists and nuclear medicine physicians should be aware of the updated classification system and should be cognizant of the site-specific strengths and limitations of FDG PET/CT. In this article, the eighth edition of the TNM staging system is reviewed, as well as the role of FDG PET/CT in the staging of non-small cell lung carcinoma.

AB - Lung cancer is the leading cause of cancer-related mortality in the United States, and accurate staging plays a vital role in determining prognosis and treatment. The recently revised eighth edition of the TNM staging system for lung cancer defines new T and M descriptors and updates stage groupings on the basis of substantial differences in survival. There are new T descriptors that are based on the findings at histopathologic examination, and T descriptors are reassigned on the basis of tumor size and extent. No changes were made to the N descriptors in the eighth edition of the TNM staging of lung cancer, because the four N categories that are based on the location of the diseased nodes can be used to consistently predict prognosis. The eighth edition includes a new M1b descriptor for patients with a single extrathoracic metastatic lesion in a single organ (M1b), because they have better survival and different treatment options, compared with those with multiple extrathoracic lesions (M1c). Examination with fluorine 18 fluorodeoxyglucose (FDG) PET/CT is the standard of care and is an integral part of the clinical staging of patients with lung cancer. To provide the treating physicians with accurate staging information, radiologists and nuclear medicine physicians should be aware of the updated classification system and should be cognizant of the site-specific strengths and limitations of FDG PET/CT. In this article, the eighth edition of the TNM staging system is reviewed, as well as the role of FDG PET/CT in the staging of non-small cell lung carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85056497252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056497252&partnerID=8YFLogxK

U2 - 10.1148/rg.2018180060

DO - 10.1148/rg.2018180060

M3 - Article

VL - 38

SP - 2134

EP - 2149

JO - Radiographics

JF - Radiographics

SN - 0271-5333

IS - 7

ER -